Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 11/06/26
Moderna Earnings Preview: The Melanoma Breakthrough Is Real, But $221 Is Way Too MuchSeeking Alpha • 11/05/26
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its SuccessThe Motley Fool • 11/03/26
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial24/7 Wall Street • 11/03/26
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This WeekBarrons • 11/01/26
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up24/7 Wall Street • 10/30/26
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks Investment Research • 10/29/26
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to KnowZacks Investment Research • 10/29/26
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's workWSJ • 10/28/26
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher24/7 Wall Street • 10/28/26
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityThe Motley Fool • 10/28/26
William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% RunBenzinga • 10/27/26